Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic- Antiresorptive Mechanisms Post date October 16, 2026 ← Exploring the Potential of Ayurveda in Developing Sustainable and Reliable Treatment Options for the Future → Integrating Transcriptomic and Epigenomic Data to Identify Potential Biomarkers in Gestational Diabetes Mellitus Patients